These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38436356)

  • 21. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials.
    Cortese A; Machado P; Morrow J; Dewar L; Hiscock A; Miller A; Brady S; Hilton-Jones D; Parton M; Hanna MG
    Neuromuscul Disord; 2013 May; 23(5):404-12. PubMed ID: 23489664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.
    Chahin N; Engel AG
    Neurology; 2008 Feb; 70(6):418-24. PubMed ID: 17881720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inclusion body myositis in twins.
    Amato AA; Shebert RT
    Neurology; 1998 Aug; 51(2):598-600. PubMed ID: 9710045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring hand and upper limb function in patients with inclusion body myositis (IBM).
    Hunn S; Alfano L; Seiffert M; Weihl CC
    Neuromuscul Disord; 2023 Aug; 33(8):643-650. PubMed ID: 37451936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Muscle fiber dysfunction contributes to weakness in inclusion body myositis.
    Lassche S; Rietveld A; Heerschap A; van Hees HW; Hopman MT; Voermans NC; Saris CG; van Engelen BG; Ottenheijm CA
    Neuromuscul Disord; 2019 Jun; 29(6):468-476. PubMed ID: 31101463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inclusion body myositis.
    Dimachkie MM; Barohn RJ
    Curr Neurol Neurosci Rep; 2013 Jan; 13(1):321. PubMed ID: 23250766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-patient comorbidities in inclusion body myositis: a United States national in-patient sample-based study.
    Ma AK; Dai F; Roy B
    Clin Exp Rheumatol; 2023 Mar; 41(2):261-266. PubMed ID: 36377563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inclusion body myositis: diagnosis, pathogenesis, and treatment options.
    Solorzano GE; Phillips LH
    Rheum Dis Clin North Am; 2011 May; 37(2):173-83, v. PubMed ID: 21444018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring challenges in the management and treatment of inclusion body myositis.
    Skolka MP; Naddaf E
    Curr Opin Rheumatol; 2023 Nov; 35(6):404-413. PubMed ID: 37503813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inclusion body myositis: The interplay between ageing, muscle degeneration and autoimmunity.
    McLeish E; Slater N; Sooda A; Wilson A; Coudert JD; Lloyd TE; Needham M
    Best Pract Res Clin Rheumatol; 2022 Jun; 36(2):101761. PubMed ID: 35760741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inclusion body myositis: therapeutic approaches. A case report.
    Kierdaszuk B; Kamińska A
    Neurol Neurochir Pol; 2011; 45(1):68-73. PubMed ID: 21384296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inclusion body myositis: clinical features and pathogenesis.
    Greenberg SA
    Nat Rev Rheumatol; 2019 May; 15(5):257-272. PubMed ID: 30837708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sporadic Inclusion Body Myositis].
    Aoki M; Izumi R; Suzuki N
    Brain Nerve; 2024 May; 76(5):660-670. PubMed ID: 38741510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosing and managing dysphagia in inclusion body myositis: a systematic review.
    Ambrocio KR; Garand KLF; Roy B; Bhutada AM; Malandraki GA
    Rheumatology (Oxford); 2023 Oct; 62(10):3227-3244. PubMed ID: 37115631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inclusion body myositis (IBM).
    Gayathri N; Anisya-Vasanth ; Veerendra Kumar M; Das S; Santosh V; Yasha TC; Ramamohan Y; Taly AB; Gourie-Devi M; Shankar SK
    Clin Neuropathol; 2000; 19(1):13-20. PubMed ID: 10774946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inclusion body myositis and sarcoid myopathy: coincidental occurrence or associated diseases.
    Sanmaneechai O; Swenson A; Gerke AK; Moore SA; Shy ME
    Neuromuscul Disord; 2015 Apr; 25(4):297-300. PubMed ID: 25599912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Sporadic Inclusion Body Myositis].
    Yamashita S
    Brain Nerve; 2023 Jul; 75(7):869-874. PubMed ID: 37431078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings.
    Pinto MV; Laughlin RS; Klein CJ; Mandrekar J; Naddaf E
    Rheumatology (Oxford); 2022 May; 61(6):2504-2511. PubMed ID: 34617994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysphagia as the Presenting Symptom for Inclusion Body Myositis.
    Esteban MJ; Kassar D; Padilla O; McCallum R
    J Investig Med High Impact Case Rep; 2021; 9():23247096211050211. PubMed ID: 34886694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.
    Mendell JR; Sahenk Z; Al-Zaidy S; Rodino-Klapac LR; Lowes LP; Alfano LN; Berry K; Miller N; Yalvac M; Dvorchik I; Moore-Clingenpeel M; Flanigan KM; Church K; Shontz K; Curry C; Lewis S; McColly M; Hogan MJ; Kaspar BK
    Mol Ther; 2017 Apr; 25(4):870-879. PubMed ID: 28279643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.